Compare Quest Diagnostics Inc (DGX) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs NICE Ltd — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while NICE Ltd trades at $102.43 (market cap $6.00B). The key difference: Quest Diagnostics Inc is far larger — about 3.8× NICE Ltd's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| DGX | NICE | |
|---|---|---|
Market Cap | $22.80B | $6.00B |
Sector | Health | Technology |
52-Week High | $216.02 | $170.37 |
52-Week Low | $166.42 | $83.15 |
Enterprise Value | $28.82B | $5.78B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NICE stock trades at $103.48, up 3.75% today, with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with a 65.79% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.64 beating expectations of $2.52. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, expanding NICE's global footprint in customer experience solutions.
NICE presents a compelling investment case with attractive valuation (P/E 12.13) and 56.5% analyst buy ratings targeting $124.88 consensus. Key risks include execution challenges in AI integration and competitive pressure from larger tech players. The stock's current proximity to 52-week highs requires monitoring for sustainability of recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
